{"title":"丙型病毒性肝炎患者中艾滋病毒相关耐药结核病治疗效果不佳的预测因素","authors":"A. V. Kukurika","doi":"10.22625/2072-6732-2024-16-2-81-88","DOIUrl":null,"url":null,"abstract":"The aim of study – to identify predictors of unfavorable outcomes in patients with co-morbidities of multidrug-resistant tuberculosis (MDR-TB); HIV infection; and viral hepatitis C (HCV) to optimize care.Materials and Methods. A total of 132 patients with MDRTB/HIV/HCV triple infection were included in the study: 112 individuals with favorable outcomes and 20 patients with unfavorable outcomes. To assess predictors of unfavorable outcomes; odds ratios and 95% confidence intervals were calculated. 95% confidence interval were calculated; and a prognostic model was built using logistic regression.Results. Generalization tuberculosis process increased the chance of unfavorable outcome by 8.13 times (95% CI: 2.252 – 29.354; p<0.001); treatment with chemotherapy regimens without the inclusion of the new highly effective antituberculosis drugs – 5.333 times (95% CI: 0.059 – 0.597; p=0.002); undesirable adverse drug reactions – 4.263 times (95% CI: 0.938 to 19.370; p=0.044); severe adverse drug reactions – 6.429 times (95% CI: 1.889 – 21.878; p=0.001); level of CD4-lymphocyte count less than 50 cells/µL – 7 times (95% CI: 2.180 – 22.482; p<0.001); stage 4B HIV infection – 4.1 times (95% CI: 1.527 – 11.007; p=0.003).Conclusion. The results obtained indicate the need to further study the problem of HIV-associated MDR-TB in combination with HCV in order to develop evidence-based algorithms for the management of this category of patients; taking into account the identified predictors of unfavorable treatment outcomes.","PeriodicalId":226950,"journal":{"name":"Journal Infectology","volume":"15 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors of unfavourable treatment outcomes for HIV-associated MDR-TB in patients with viral hepatitis C\",\"authors\":\"A. V. Kukurika\",\"doi\":\"10.22625/2072-6732-2024-16-2-81-88\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of study – to identify predictors of unfavorable outcomes in patients with co-morbidities of multidrug-resistant tuberculosis (MDR-TB); HIV infection; and viral hepatitis C (HCV) to optimize care.Materials and Methods. A total of 132 patients with MDRTB/HIV/HCV triple infection were included in the study: 112 individuals with favorable outcomes and 20 patients with unfavorable outcomes. To assess predictors of unfavorable outcomes; odds ratios and 95% confidence intervals were calculated. 95% confidence interval were calculated; and a prognostic model was built using logistic regression.Results. Generalization tuberculosis process increased the chance of unfavorable outcome by 8.13 times (95% CI: 2.252 – 29.354; p<0.001); treatment with chemotherapy regimens without the inclusion of the new highly effective antituberculosis drugs – 5.333 times (95% CI: 0.059 – 0.597; p=0.002); undesirable adverse drug reactions – 4.263 times (95% CI: 0.938 to 19.370; p=0.044); severe adverse drug reactions – 6.429 times (95% CI: 1.889 – 21.878; p=0.001); level of CD4-lymphocyte count less than 50 cells/µL – 7 times (95% CI: 2.180 – 22.482; p<0.001); stage 4B HIV infection – 4.1 times (95% CI: 1.527 – 11.007; p=0.003).Conclusion. The results obtained indicate the need to further study the problem of HIV-associated MDR-TB in combination with HCV in order to develop evidence-based algorithms for the management of this category of patients; taking into account the identified predictors of unfavorable treatment outcomes.\",\"PeriodicalId\":226950,\"journal\":{\"name\":\"Journal Infectology\",\"volume\":\"15 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal Infectology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22625/2072-6732-2024-16-2-81-88\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Infectology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22625/2072-6732-2024-16-2-81-88","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Predictors of unfavourable treatment outcomes for HIV-associated MDR-TB in patients with viral hepatitis C
The aim of study – to identify predictors of unfavorable outcomes in patients with co-morbidities of multidrug-resistant tuberculosis (MDR-TB); HIV infection; and viral hepatitis C (HCV) to optimize care.Materials and Methods. A total of 132 patients with MDRTB/HIV/HCV triple infection were included in the study: 112 individuals with favorable outcomes and 20 patients with unfavorable outcomes. To assess predictors of unfavorable outcomes; odds ratios and 95% confidence intervals were calculated. 95% confidence interval were calculated; and a prognostic model was built using logistic regression.Results. Generalization tuberculosis process increased the chance of unfavorable outcome by 8.13 times (95% CI: 2.252 – 29.354; p<0.001); treatment with chemotherapy regimens without the inclusion of the new highly effective antituberculosis drugs – 5.333 times (95% CI: 0.059 – 0.597; p=0.002); undesirable adverse drug reactions – 4.263 times (95% CI: 0.938 to 19.370; p=0.044); severe adverse drug reactions – 6.429 times (95% CI: 1.889 – 21.878; p=0.001); level of CD4-lymphocyte count less than 50 cells/µL – 7 times (95% CI: 2.180 – 22.482; p<0.001); stage 4B HIV infection – 4.1 times (95% CI: 1.527 – 11.007; p=0.003).Conclusion. The results obtained indicate the need to further study the problem of HIV-associated MDR-TB in combination with HCV in order to develop evidence-based algorithms for the management of this category of patients; taking into account the identified predictors of unfavorable treatment outcomes.